Reuters logo
BRIEF-Leap Therapeutics announces collaboration with EORTC
September 8, 2017 / 11:16 AM / in 3 months

BRIEF-Leap Therapeutics announces collaboration with EORTC

Sept 8 (Reuters) - Leap Therapeutics Inc

* Leap Therapeutics announces collaboration with EORTC to evaluate DKN-01 in combination with PD-l1 cancer immunotherapy and chemotherapy in esophagogastric and biliary tract cancers

* Leap Therapeutics Inc - ‍Roche will supply atezolizumab to EORTC for this study collaboration​

* Leap Therapeutics Inc - ‍study is expected to begin enrolling patients in 2018​

* Leap Therapeutics - ‍study aims to understand synergy between DKN-01, a WNT-targeted therapy, and immune checkpoint inhibitor with and without chemotherapy​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below